



28 September 2018

ASX Announcement

Notification of 2018 Annual General Meeting Date

28 September 2018: Race Oncology Limited ('RAC') advises, in accordance with ASX Listing Rule 3.13.1, that its Annual General Meeting will be held at the ISC Room, RACA, 89 Macquarie Street, Sydney, New South Wales, on Tuesday, 27 November 2018 at 11.00 am AEDT.

-ends-

About Bisantrene

Bisantrene is a chemotherapy drug that was tested in more than 40 clinical studies before it was lost in a series of pharmaceutical mergers in the 1990s. Race is rediscovering and rescuing Bisantrene and the initial clinical opportunity is for treatment of relapsed/refractory AML. Race owns two recent patents on the drug, both of which have been granted in the US. Bisantrene has also been granted an Orphan Drug Designation in the US for AML, which confers seven years of market exclusivity in US from date of FDA approval; and Rare Paediatric Disease designation in the US, which could lead to a valuable Priority Review Voucher.

About Race Oncology (RAC.ASX)

Race Oncology is a specialty pharmaceutical company that listed on the Australian Securities Exchange (ASX) in July 2016. Race's business model is to pursue later-stage drug assets in the cancer field that have been overlooked by big pharma. The company's first asset is Bisantrene. Race has successfully manufactured Bisantrene and is seeking to complete the development necessary to gain FDA approval, while also making the drug available as an unlicensed medication under named patient programs outside the US.

Media contact:

Heidi Cuthbert, +61 411 272 366;
E: heidi.cuthbert@multiplier.com.au